Stockscreener 앱 받기
1.70
15.00%
-0.30
시간 외 거래:
1.61
-0.09
-5.29%
전일 마감가:
$2.00
열려 있는:
$1.77
하루 거래량:
378.28K
Relative Volume:
0.11
시가총액:
$987.65K
수익:
$856.00K
순이익/손실:
$-12.56M
주가수익비율:
-0.00734
EPS:
-231.4926
순현금흐름:
$-4.14M
1주 성능:
-61.97%
1개월 성능:
-63.68%
6개월 성능:
-59.91%
1년 성능:
-95.19%
1일 변동 폭
$1.60
$1.97
1주일 범위
$1.60
$5.3299
52주 변동 폭
$1.60
$40.41
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
1.70 | 987.65K | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Scisparc Ltd 주식(SPRC)의 최신 뉴스
No cash would flow to SciSparc (SPRC) under a proposed debt-for-shares conversion. - Stock Titan
Net loss narrows to $6.05M, but SciSparc (SPRC) raises substantial doubt about continuing operations. - Stock Titan
First human trial gets approval as Polyrizon (PLRZ) reports a wider six-month loss. - Stock Titan
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome - OTC Markets
SciSparc Awarded Three Patents For Its Novel Compounds and Methods - OTC Markets
Scisparc Ltd (SPRC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial - TipRanks
Tourette drug cut tics 21% in study as SciSparc (SPRC) advances trials - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - The Manila Times
A Tourette drug candidate achieved an average 21% tic reduction in an earlier study - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - marketscreener.com
SciSparc Ltd. SEC Filing (Sep 1, 2026) - Stock Titan
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - The Manila Times
26 children have joined SciSparc’s two-compound autism treatment trial - Stock Titan
Neurothera Labs Inc. Announces Share Consolidation - TradingView
Neurothera Labs Inc. Announces Share Consolidation - FinancialContent
Neurothera Labs Inc. Announces Share Consolidation - TheNewswire
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com South Africa
SciSparc appoints AI professor to advisory board - Investing.com
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com Canada
SciSparc appoints AI professor to advisory board By Investing.com - Investing.com India
Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026 - marketscreener.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionIV Crush Alert - vinanet.vn
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com Canada
SciSparc (SPRC) adds MDMA-PEA PTSD patent with Clearmind - Stock Titan
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com India
SciSparc subsidiary publishes MDMA combination patent application By Investing.com - Investing.com UK
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionCommon Gap - careplusvn.com
SciSparc (SPRC) Levels: Finishes 1.50% Up at $6.78 in the Current Update; Market Levels: Support at $6.44 and Resistance at $7.12 Frame the Range for the Current SessionSpring Pattern - dars.gov.et
FDA Guidance Includes MDMA as a Psychedelic Drug; SciSparc Patent Application Published - Stock Titan
SciSparc Ltd.Ordinary Shares (NQ: SPRC - The Chronicle-Journal
SciSparc | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment) - Moomoo
Scisparc posts audited 2025 net loss of USD 12.56 million - Bitget
SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A) - marketscreener.com
SciSparc Boosts NeuroThera Stake in C$5.4 Million Financing - TipRanks
SciSparc (NASDAQ: SPRC) backs NeuroThera in C$5.4M raise - Stock Titan
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round - AllSci
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com
SciSparc invests C$2.7M in subsidiary NeuroThera financing By Investing.com - Investing.com Canada
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Moomoo
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 - GlobeNewswire
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - Yahoo Finance
SciSparc Invests C$2.7 Million in NeuroThera Financing, Increases Stake to Approximately 44.6% - Quiver Quantitative
SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million - The Manila Times
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TradingView
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZonePut Call Ratio - vinanet.vn
SciSparc (SPRC) Gains 1.59% as Shares Hold Firm Above $6 Support ZoneRevenue Growth Stocks - dars.gov.et
Scisparc Ltd (SPRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Scisparc Ltd 주식 (SPRC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shrem Itschak | Director |
Jun 01 '26 |
Sale |
10.00 |
462 |
4,620 |
10,596 |
4.22%
자본화:
|
볼륨(24시간):